-
Is Alexion a "Pricey" One-Trick Pony?
Tuesday, March 27, 2012 - 11:23am | 610Read More...Alexion Pharmaceuticals (NASDAQ: ALXN) shares have appreciated over 30 percent this year alone. It currently trades at over 55 times its expected 2012 earnings, quite a bit higher than the mid-teens price-to-earnings seen across its biotech peers. The company focuses on an extremely rare niche and...
-
Biogen Idec Price Target Raised to $60 at MP Advisors
Friday, November 26, 2010 - 10:44am | 21Read More...Biogen Idec (NASDAQ: BIIB) price target is raised from $56 to $60 at MP Advisors.
-
Amgen Downgraded to Market Perform at MP Advisors
Monday, November 22, 2010 - 12:14pm | 27Read More...Amgen (NASDAQ: AMGN) is downgraded from Outperform to Market Perform at MP Advisors. Price target has decreased from $65 to $63.
